… Based on the rationales, we hypothesized that low-dose erlotinib would be safe and …
multicenter phase 2 clinical trial to investigate the efficacy and safety of low-dose erlotinib in …

… patients to erlotinib treatment, 40 patients to cabozantinib treatment, and … erlotinib in wild-type
EGFR NSCLC formed the basis for the selection of the erlotinib control group in this study …

… Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors …
a phase II study to determine the clinical activity of sorafenib in combination with erlotinib in …

… , 2018, for clinical trials published in English using the search terms “erlotinib”, “bevacizumab”…
phase 2 trials that assessed the activity of erlotinib plus bevacizumab as first-line treatment …

… However, these trials were performed in unselected patients without EGFR … phase 2 trial
has compared erlotinib + RT and CCRT in patients with EGFRm-positive unresectable stage III …

… study was a randomised, multicentre, phase 2 trial that compared bevacizumab–erlotinib
with erlotinib alone as first-line treatments in 154 … In the JO25567 study, bevacizumab–erlotinib …

… , multicenter, randomized Phase 2 study in South Korea. Chemonaïve patients with Stage
… Asymptomatic brain metastasis (BM) was enrolled without local treatment. Patients received …

… multicenter, randomized, open-label phase II trial compared the objective response rate (ORR)
as defined by RECIST 1.0 in the erlotinib plus fulvestrant arm versus erlotinib … 2:1 by a …

… a randomized phase II trial, evaluating the efficacy of a combined EGFR inhibition using
erlotinib and panitumumab in conjunction with gemcitabine with gemcitabine plus erlotinib as a …

… Study design and participants BELIEF was an international, multicentre, single-arm,
phase 2 trial to test the efficacy of the combination of erlotinib and bevacizumab in treatment-naive …